ArticleJournal of gastrointestinal oncology2026
Cadonilimab plus chemotherapy
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity?Journal of gastrointestinal oncology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cadonilimab (AK104) is a first-in-class bispecific antibody targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). This study evaluated the effectiveness and safety of cadonilimab plus chemotherapy Methods: Between August 2022 and August 2024, patients with PD-L1 CPS <5 G/GEJ cancer who received first-line cadonilimab plus chemotherapy (cadonilimab group) or PD-1 inhibitor plus chemotherapy (PD-1 inhibitor group) were included. After propensity score matching (PSM), the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety were analyzed. Results: Fifty-two patients were analyzed after PSM (26 per group). At data cutoff (February 28, 2025), median follow-up was 11.0 months [95% confidence interval (CI): 8.3-15.3]. Compared with the PD-1 inhibitor group, cadonilimab group exhibited a numerically higher ORR (73.3% Conclusions: Compared to PD-1 inhibitor plus chemotherapy, cadonilimab plus chemotherapy significantly improved PFS and OS with a manageable safety profile in the first-line treatment of advanced G/GEJ cancer with PD-L1 CPS <5 in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.